Trading in Regeneron Common Stock Halted
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Regeneron (REGN) Resumes Trading Up 1%
June 9, 2015 6:50 PM EDTRegeneron (NASDAQ: REGN) resumed trading up 1% after confirming FDA panel backing of Praluent injection.
... MoreRegeneron (REGN) to Resume Trading at 6:50PM ET
June 9, 2015 6:36 PM EDTRegeneron (NASDAQ: REGN) is set to resume trading at 6:50PM ET after confirming FDA panel backing of Praluent.
... MoreRegeneron (REGN) Confirms FDA Panel Backing of Praluent
June 9, 2015 6:34 PM EDTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) confirmed that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended the approval of the investigational therapy Praluent® (alirocumab) Injection.
The Committee voted 13 to three (with no abstentions) that Regeneron and Sanofi had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
"We are pleased with the Committee's recommendation to approve Praluent. Our clinical trial program... More
